Zoetis:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230809927875/en/

Zoetis CEO Kristin Peck (center), cuts the ribbon, marking the official opening of the company's new monoclonal antibodies (mAbs) expansion. Ms. Peck is pictured with Zoetis leadership and local officials. Source: Zoetis

NEWS FACTS

• Today, Zoetis, the world leader in Animal Health, marked the official opening of its new monoclonal antibodies (mAbs) expansion with a ribbon cutting ceremony at its site in Lincoln, Neb.
• The ceremony was attended by local officials, including U.S. Senator Pete Ricketts, Lincoln Mayor Gaylor Baird and key company leaders including Zoetis CEO Kristin Peck, and President of Global Manufacturing and Supply, Nick Ashton.
• This new facility will enable the Lincoln manufacturing site to increase production of products that control osteoarthritis pain in dogs and cats – the company’s largest growing area of need for pet care customers.
• The new facility will also be a home for future innovation and serve as a Veterinary Medicine R&D registration facility for the company as it looks to expand its portfolio with future innovations.

ZOETIS IN LINCOLN

• Zoetis’ Lincoln site in Neb. is a crucial manufacturing plant within the Zoetis supply network. It plays a vital role in producing biologics, biopharmaceuticals and pharmaceutical products for animals.
• With a workforce of nearly 950 colleagues operating 24/7, year-round, the site manufactures an impressive 1,239 finished goods, or stock keeping units (SKUs), for distribution to more than 100 countries worldwide.
• Located on 145 acres in the west side of Lincoln, Neb., the campus spans 1.4 million square feet, housing manufacturing, testing, and facility support buildings.
• Zoetis produces some of its flagship vaccines and pharmaceutical products in Lincoln, including:
  • Cytopoint^® - a monoclonal antibody that provides effective treatment for dogs against allergic or atopic dermatitis,
  • Vanguard^® - a line of vaccines to keep dogs and cats protected from common diseases,
  • BoviShield^® - a line of vaccines shown to be efficacious against respiratory diseases, and reproductive diseases for the specific BoviShield FP line, in cattle,
  • Simparica^® (sarolaner) - a parasiticide that protects dogs from ticks and fleas. Simparica^® belongs to the Isoxazoline drug class and has been associated with neurologic adverse reactions including seizures. Use with caution in dogs with a history of these conditions. The most common side effects are vomiting and diarrhea.
  • Rimadyl^® (carprofen) - a pharmaceutical product for relief of pain associated with osteoarthritis in dogs. Rimadyl^® belongs to the NSAIDS drug class and has been associated with gastrointestinal, kidney and liver side effects; contact your dog’s veterinarian if side effects occur. Evaluation for pre-existing conditions and regular monitoring are recommended for pets on Rimadyl^®. Use with other NSAIDS or corticosteroids should be avoided.
• Zoetis and its predecessors have long maintained a presence in the Lincoln area. In the early 20th century, pharmaceutical firms and distributors such as Norden Laboratories established facilities in Nebraska that evolved over time. More recent incarnations of these animal health companies, including Zoetis, have continued to play an important economic role in the Lincoln community.

QUOTES

“We are excited to celebrate the opening of our new facility right here in Nebraska! This community is important to us as we have been welcomed to do business here for over a decade as Zoetis, delivering high quality, reliable supply of our animal health products for customers around the world,” said Chris Rasmussen, Zoetis Site Leader, Lincoln. “For the last 10 years, we have been able to grow our business, expand our site and bring more than 900 jobs to the site in Lincoln based on the world’s fundamental need for ways to keep animals healthy.”

“Our Zoetis Lincoln team has always demonstrated a commitment to the world’s veterinary community and livestock producers by delivering purpose-driven innovation that transforms the lives of animals from cats to cattle -- and it’s why we continue to invest in the operations and colleagues here,” said Kristin Peck, CEO Zoetis. “This new monoclonal antibody (mAbs) expansion will enable us to continue meeting the needs of our customers in one of the fastest growing areas of animal health, and our team in Lincoln will be critical to that future.”

ABOUT ZOETIS

As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide -- from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.1 billion in 2022 with approximately 13,800 employees. For more information, visit www.zoetis.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230809927875/en/